Antiretroviral therapy (ART) prevented premature mortality and improved the quality of life among people living with the human immunodeficiency virus (PLWH), such that now more than half of PLWH in the United States are 50 years of age and older. Increased longevity among PLWH has resulted in a significant rise in chronic, comorbid diseases. However, the implementation of guideline-based interventions for preventing, treating, and managing such age-related, chronic conditions among the HIV population is lacking. The PRECluDE consortium supported by the Center for Translation Research and Implementation Science at the National Heart, Lung, and Blood Institute catalyzes implementation research on proven-effective interventions for co-occurring heart, lung, blood, and sleep diseases and conditions among PLWH. These collaborative research studies use novel implementation frameworks with HIV, mental health, cardiovascular, and pulmonary care to advance comprehensive HIV and chronic disease healthcare in a variety of settings and among diverse populations.

中文翻译：

---

为艾滋病毒感染者制定干预措施的实施研究（PRECluDE 联盟）：通过实施研究对抗艾滋病毒人群的慢性疾病合并症。


抗逆转录病毒疗法 (ART) 预防了人类免疫缺陷病毒 (PLWH) 感染者的过早死亡并改善了他们的生活质量，目前美国一半以上的 PLWH 年龄在 50 岁及以上。艾滋病病毒感染者寿命的延长导致慢性合并症的显着增加。然而，缺乏针对艾滋病毒人群中此类与年龄相关的慢性病的预防、治疗和管理的基于指南的干预措施的实施。由国家心肺血液研究所翻译研究和实施科学中心支持的 PRECluDE 联盟促进针对 PLWH 中同时发生的心、肺、血液和睡眠疾病和病症的经证明有效的干预措施的实施研究。这些合作研究利用艾滋病毒、心理健康、心血管和肺部护理的新颖实施框架，在各种环境和不同人群中推进全面的艾滋病毒和慢性病医疗保健。